Japan's Science research and Kobe University authorized Lingke Pharmaceuticals to develop new RAS inhibitors exclusively.

Guide: RAS is the leading cause of many cancers, including pancreatic cancer (95%), colon cancer (50%) and lung adenocarcinoma (30%).!----, Lingco Pharmaceuticals recently announced an exclusive licensing agreement with Kobe University of Japan and the Japan Institute of Science and Chemistry (RIKEN) to develop RAS inhibitors with a new drug mechanism (MOA).also, the agreement between Lingke Pharmaceuticals and Kobe University also includes continued technical support for active screening and structure sedits by Kobe University.RAS are the main causes of many cancers, including pancreatic cancer (95%), colon cancer (50%) and lung adenocarcinoma (30%).RAS has been a target for the medical community since it was first discovered in the 1960s, but the results have been very limited.has made progress in recent years with KRAS G12C mutations through irreversible binding inhibitors, the therapy has failed to suppress other, more common KRAS mutations, such as G12V and G12D. "Lingco Pharmaceuticals will use its expertise in pharmaceutical chemistry and drug design to develop better RAS inhibitors for a wider range of 'non-drugable' RAS-induced malignancies and ultimately clinically effective drugs based on the results of early structural biology and screening at Kobe University and RIKEN," said Dr. Wan Zhaokui, founder, chairman and CEO ofLingke Pharmaceuticals.this is an ambitious drug development process for us, and we are challenging a target that has been 'non-drugable' for decades, but we believe that by working with two world-renowned research institutions to develop new targeted drugs using new drug mechanisms, we will certainly offer greater hope to cancer patients."